FOXO4 10mg/vial For Bodybuilding CAS:2460055-10-9

   What is FOXO4 10mg?

    FOXO4 10mg refers to a vial or capsule containing 10 milligrams of a peptide compound known as FOXO4-DRI (FOXO4-D-Retro-Inverso). This is not a hormone, anabolic steroid, or SARMs. It is a scientifically engineered peptide designed to interfere with a specific protein-protein interaction within cells.

    The name derives from the Forkhead box O (FOXO) family of transcription factors, specifically FOXO4. These proteins play a pivotal role in cellular processes like apoptosis (programmed cell death), stress resistance, and metabolism. The "DRI" stands for D-Retro-Inverso, a sophisticated peptide design strategy that creates a mirror-image version of a natural peptide sequence. This makes the molecule highly resistant to degradation by proteolytic enzymes in the body, significantly extending its potential activity window compared to a natural peptide.

    It is sold exclusively for scientific research purposes, typically in lyophilized (freeze-dried) powder form requiring reconstitution with bacteriostatic water for in-vitro or animal model studies.

    The theoretical foundation for FOXO4's interest in bodybuilding and recovery lies in its targeted action on .

    As cells experience stress or damage (e.g., from oxidative stress, intense exercise, or aging), they can enter a state called senescence. They don't die, but they stop dividing and begin secreting a potent mix of inflammatory cytokines, growth factors, and proteases known as the Senescence-Associated Secretory Phenotype (SASP). SASP creates a chronically inflammatory local environment that damages surrounding healthy tissues, impairs regeneration, and is a primary driver of aging and age-related diseases.

    A key mechanism that keeps senescent cells alive involves an interaction between the FOXO4 protein and another protein called p53. Normally, p53 promotes cell death. However, in senescent cells, FOXO4 binds to p53 and prevents it from executing this apoptotic function, effectively allowing the "zombie" senescent cell to persist and continue secreting harmful SASP factors.

    FOXO4-DRI is designed as a competitive inhibitor. Its structure allows it to bind tightly to FOXO4 with a higher affinity than p53. By doing so, it blocks the FOXO4-p53 interaction. With this interaction disrupted, p53 is freed to perform its normal pro-apoptotic function, triggering the programmed death of the senescent cell without affecting healthy, non-senescent cells. This process is termed "senolysis" (killing of senescent cells).

.

    1.Accelerated Recovery: Intense resistance training induces significant muscle damage and cellular stress, potentially leading to the accumulation of senescent cells in muscle tissue and surrounding structures. The SASP from these cells could contribute to delayed onset muscle soreness (DOMS), prolonged fatigue, and a longer recovery period. By clearing these cells, FOXO4-DRI could, in theory, drastically reduce recovery time, allowing an athlete to train with higher frequency and intensity.

    2.Reduction of Systemic Inflammation: The chronic, low-grade inflammation from systemic SASP can hinder muscle growth, promote joint stiffness, and impair overall well-being. A senolytic agent could lower this inflammatory burden, creating a more anabolic environment conducive to growth and repair.

    3.Joint Health and Tendon Repair: Cartilage and tendon cells are particularly prone to senescence, which contributes to joint pain and degenerative conditions. Eliminating these cells could potentially alleviate joint pain and improve the integrity of connective tissues, a significant limiting factor for many serious bodybuilders.

    4.Potential for "Recomposition": By improving metabolic function and reducing inflammatory barriers, a theoretical outcome could be an improved ability to lose fat while preserving or even building muscle, though this is highly speculative.

    ●Drastically reduced muscle soreness and recovery time.

    ●Decreased systemic inflammation.

    ●Improved joint health and pain reduction.

    ●Potential for increased training frequency and volume.

    ●Non-hormonal mechanism of action (does not suppress the HPTA).

    ● All prominent research on FOXO4-DRI is from animal models (mice). Human physiology, dosing, side effects, and long-term consequences are completely unknown.

    ●Off-Target Effects: While designed to be specific, the potential for unintended interactions with other cellular processes is a serious risk.

    ● Anecdotal reports from the research chemical community mention severe "die-off" reactions, including intense nausea, fever, and fatigue following administration, likely due to the rapid clearance of a large number of senescent cells and the subsequent immune response to clean up the debris.

    ● As an unregulated research chemical, product purity, sterility, and accurate dosing are massive concerns. Contamination presents a severe health risk.

    ●Long-Term Consequences: The role of senescence is complex. Some senescent cells are beneficial, such as in wound healing and embryonic development. Indiscriminate senolysis could have unforeseen negative consequences.

    Important Disclaimer: The following information is extrapolated from rodent studies and anecdotal reports from research chemical users. It is not a recommendation for human use.

    ●Half-Life: The D-retro-inverso modification grants FOXO4-DRI a significantly longer half-life than a natural peptide. Estimates based on its properties suggest a half-life in the range of several hours to potentially a day in a rodent model. Human pharmacokinetics are unknown.

    ● In the limited preclinical studies, dosing was calculated based on mg per kg of body weight. Anecdotal human protocols are extremely variable and unscientific. Some experimental regimens suggest a single dose of 5-10mg for a human subject, but this is purely guesswork.

    ● The defining feature of senolytics is that they are not meant for continuous use. Senescent cells take time to re-accumulate. Therefore, the proposed protocol is . A common theoretical cycle is a single dose once every 1-2 weeks, or even once a month. This allows for the clearance of senescent cells without the need for constant administration. Cycles might be employed for 2-3 months followed by an extended off-period.

	FOXO4, AFX, AFX1, MLLT7, forkhead box O4
	2460055-10-9
	5358.06
	C250H432N86O86
	Above 98%
	10mg/vial,Lyophilized powder

 

 

Email: Jasonraws106@gmail.com

WhatsApp: +86-15572565525
Telegram: +86-15871669785

   

                                   

 

    FOXO4 10mg (FOXO4-DRI) represents a fascinating and powerful tool for biological research, offering profound insights into the role of cellular senescence in aging and disease. Its potential application in bodybuilding is a logical extrapolation: by removing inflammatory senescent cells, one could theoretically create an internal environment that favors rapid recovery and reduced pain.

. The jump from mouse models to human application is vast and fraught with danger. The complete lack of human safety data, coupled with the risks of an unregulated research chemical market, makes any attempt at human use highly reckless and ill-advised.

    For the scientific community, FOXO4-DRI is a promising compound that validates the senolytic approach. For the bodybuilding community, it should remain a subject of interest to be watched from a distance as legitimate clinical science develops, not a compound to be experimented with based on anecdotal reports and speculative mechanisms. 

Beliebte label: foxo4 10mg/vial for bodybuilding cas:2460055-10-9, China foxo4 10mg/vial for bodybuilding cas:2460055-10-9 manufacturers, suppliers, factory